COVID-19 update: Baricitinib (Olumiant) FDA-approved for treatment of COVID-19.

WHO COVID-19 Research Database

News/Update/Help

Advanced Search

The WHO Covid-19 Research Database is a resource created in response to the Public Health Emergency of International Concern (PHEIC). Its content remains searchable and spans the time period March 2020 to June 2023. Since June 2023, manual updates to the database have been discontinued.

COVID-19 update: Baricitinib (Olumiant) FDA-approved for treatment of COVID-19.

Med Lett Drugs Ther ; 64(1652): e2-e3, 2022 06 13.

Article in English | MEDLINE | ID: covidwho-1876765

Subject(s)

Azetidines; COVID-19 Drug Treatment; Azetidines/adverse effects; Humans; Purines/therapeutic use; Pyrazoles; Sulfonamides

Keywords

COVID-19; Olumiant; baricitinib; dosage; efficacy

Search on Google

Print

XML

PubMed Links

Collection: International databases Database: MEDLINE Main subject: Azetidines / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Med Lett Drugs Ther Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Search on Google

Print

XML

PubMed Links

Collection: International databases Database: MEDLINE Main subject: Azetidines / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Med Lett Drugs Ther Year: 2022 Document Type: Article